

Maternal Glycemia is Associated with the Perinatal Outcome in Clinical Assessments of Insulin Action in Late Pregnancy in Women at Risk for Gestational Diabetes

Loren Ekind-Hirsch*

Woman's Health Research Department, Woman's Hospital, Baton Rouge, LA, United States

Corresponding Author*

Loren Ekind-Hirsch

Woman's Health Research Department, Woman's Hospital, Baton Rouge, LA, United States

E-mail: Loren.Ekind-Hirsch@womans.org

Copyright: © 2023 Ekind-Hirsch L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01-May-2023, Manuscript No: jdm-23-24040, **Editor assigned:** 04-May-2023, Pre QC No: jdm-23-24040 (PQ), **Reviewed:** 18-May-2023, QC No: jdm-23-24040, **Revised:** 25-May-2023, Manuscript No: jdm-23-24040 (R), **Published:** 31-May-2023, DOI: 10.35248/2155-6156.10001001

Abstract

Objective: We prospectively evaluated differences in fasting- and oral glucose tolerance test (OGTT)-derived indices of insulin action in Caucasian (Cau) and African-American (AA) pregnant women and compared them with obstetric outcomes.

Study design: IRB-approved prospective study in 171 pregnant women undergoing a 3-h OGTT. Mathematical modeling was used to evaluate insulin response, insulin activity and glucose tolerance in fasting and postglucose ingestion state. Insulin sensitivity indices derived from fasting (HOMA-IR) and glucose-stimulated values (SIOGTT) were compared. An insulin sensitivity-secretion index (IS-SI) was calculated from the product of the SIOGTT and early-phase insulin secretion.

Results: Forty-nine patients had gestational diabetes (GDM), 28 had gestational impaired glucose tolerance (GIGT) and 94 had normal glucose tolerance after an abnormal glucose challenge test (NGT-abnGCT). Insulin sensitivity was lowest in women with GDM. In all groups, pregnant AA women were significantly more insulin resistant than Cau women, based on both HOMA-IR and SIOGTT, but had enhanced insulin secretion compared to their Cau counterparts. The mean IS-SI progressively improved for all women from GDM to GIGT to NGT-abnGCT. Women with NGT-abnGCT had a higher prevalence of large-for-gestational age (LGA) newborns and significantly higher cesarean section rate.

Discussion: Insulin measures along with glucose determinations during OGTT testing in pregnant women at risk for diabetes provide valuable information that varies according to race. We observed that pregnant women with a lesser degree of glucose tolerance abnormality during pregnancy who receive no intervention have a higher risk for LGA infants and significantly increased C-section rate (ClinicalTrials.gov number, NCT006874791).

Keywords: Gestational diabetes; Insulin sensitivity; Insulin secretion; Racial disparity; Perinatal outcome

Introduction

A diabetogenic condition, pregnancy is characterized by insulin resistance, hyperinsulinemia, and a compensatory increase in β -cell response. To maintain

normal glucose tolerance, normal women increase insulin secretion to compensate for insulin resistance. When insulin secretion is insufficient to compensate for the insulin resistance of pregnancy, gestational diabetes mellitus (GDM) occurs. GDM is defined as carbohydrate intolerance with onset or first recognition during pregnancy. There is a limited capacity for women with GDM to increase their insulin secretion. As a result, their glucose-stimulated insulin responses are much more muted than those of healthy pregnant women, and, respectively [1].

Women with GDM are more likely to have a cesarean section, and their babies are more likely to have macrosomia and shoulder dystocia. Any rise in the maternal glucose level appears to be associated with abnormal fetal growth in diabetic pregnancies. Even when their glucose levels are below those that are indicative of GDM, pregnant women with elevated glucose levels have a greater risk of giving birth to infants with a higher birth weight. Similar to women with GDM, pregnant women with impaired glucose tolerance exhibit insulin resistance and are more likely to have macrosomic babies and other complications [2]. Even minor degrees of increased glucose intolerance during pregnancy in women without GDM have been linked in a continuous and graded pattern to a significantly increased incidence of macrosomia, cesarean section, and pre-eclampsia, as well as an increased need for neonatal intensive care unit admission and a longer duration of maternal and neonatal hospital stay.

Ladies of ethnic minority populaces are at a more serious gamble for creating GDM. Solomon and co. found that the gamble of GDM expanded among non-Caucasian ladies in the Attendants' Wellbeing Study Associate II. Saldana et al. found a significant interaction between race and glucose status. So their examinations were delineated by race taking a gander at African-American (AA) and Caucasian (Cau) moms independently. Stoutness related gambles during pregnancy were likewise found to differ by race, with fat AA ladies bound to have unfriendly results than hefty Cau ladies [3]. Impaired glucose tolerance and glucose levels have been shown to have racially disparate effects on birth outcomes, with AA women experiencing higher levels of macrosomic babies but not Caucasians.

Gravidas with GDM typically have higher levels of post-pregnancy insulin resistance, β -cell dysfunction, central obesity, and exaggerated hyperlipidemia, suggesting that GDM is a brief symptom of ongoing metabolic dysfunction. The oral glucose resistance test (OGTT) in pregnancy can give important experiences into the hidden metabolic aggregate and chance capability of youthful, generally sound ladies [4]. Notably, a population of young women at increased risk of developing diabetes later in life is identified by the diagnosis of GDM, which is based on glucose values from an antepartum OGTT. As indicators of insulin sensitivity, researchers have frequently utilized fasting glucose and insulin levels or glucose administration levels. Kirwan et al. reported that pregnant women with normal glucose tolerance and GDM had significantly improved insulin sensitivity estimates based on glucose and insulin levels during an OGTT compared to fasting values. This study looked at how to measure insulin sensitivity and secretion in pregnant women in southern Louisiana who had varying degrees of glucose tolerance using OGTT- and fasting-derived indices. We further investigated the likely utilization of these actions to characterize racially assorted risk profiles for these pregnant ladies and contrast them and obstetric and perinatal results [5].

Materials and Methods

Treatment protocol

The protocol was approved by the Woman's Hospital Foundation's Institutional Review Board, and each participant gave written informed consent. Pregnant

ladies were approached to take an interest in the event that they met the accompanying rules as a whole: (1) gestational age between 20-30 weeks, (2) something like 18 years old, (3) were either Cau or AA and (4) had a generally simple pregnancy. This study did not include women who had previously been diagnosed with type 1 or type 2 diabetes or who were of a different ethnicity. The ladies were evaluated for starch bigotry by playing out a standard 1-h, 50-g oral glucose challenge test (GCT) between the twentieth and 28th seven day stretch of development. In the event that the plasma glucose level was more noteworthy than 135 mg/dL (GCT positive), they then, at that point, went through a 3-h, 100-g oral glucose resistance test (OGTT) [6].

176 pregnant women (135 Caucasian, 41 African American) who were referred for OGTT testing were the study's participants. After a 10- to 12-hour overnight fast, all OGTTs were carried out at the outpatient Woman's Hospital Pathology Laboratory in the early morning (7:00–9:00 AM). An interviewer-administered questionnaire was used to collect demographic, anthropometric, and clinical data on the morning of the test, including maternal age, race/ethnicity, family history of diabetes, obstetric history, and prepregnancy BMI. At 30, 60, 120, and 180 minutes following oral ingestion of 100 g glucose load, venous blood samples were taken for glucose and insulin measurement.

Laboratory measurements and physiologic indexes

As previously mentioned, glucose and insulin levels were measured while the subjects were fasting and during an oral glucose load. The conventional units of glucose and insulin (milligrams per deciliter and microunits per milliliter, respectively) were used to express insulin secretion and sensitivity. According to Matthews et al.'s description, the values of fasting were used to calculate the homeostasis model of assessment for insulin resistance (HOMA-IR). Because it mostly correlates with basal hepatic insulin resistance, the HOMA-IR typically only provides a partial estimate of body insulin sensitivity [7]. As a result, we also looked at dynamic insulin sensitivity using the Matsuda and DeFronzo OGTT insulin sensitivity (ISOGTT) model, which has been extensively validated against the glucose clamp in a variety of pathophysiological conditions. This model correlates with total glucose disposal. The HOMA-IR model did not correlate as well as ISOGTT did with insulin sensitivity derived from the glucose clamp in pregnant women. Insulin discharge was assessed after oral glucose stacking by two techniques; (1) the revised insulin reaction at glucose top (CIRgp) and (2) the insulinogenic list partitioned by HOMA-IR (IGI/HOMA-IR) which have been applied beforehand in pregnant ladies with and without GDM. During the first 30 minutes of the OGTT, the ratio of the change in insulin concentration to the change in glucose was used to calculate the insulinogenic index (IGI).

Obstetrical and perinatal outcomes

Obstetrical result data was gotten from an information base that tracks work and conveyance information for all conveyances at the Lady's Emergency clinic. Every lady's segment data, for example, age and race was gotten from the mechanized hospitalization record and affirmed with self-revealed data. By looking at the medical records of both the mother and the baby, the neonatal data were abstracted. Pregnancy weight, parity, age, race, drug or tobacco use by the mother, mode of delivery, obstetric history (previous GDM, mode of delivery), infant weight and height, gestational age at delivery, and birth weight for gestational age were all recorded. Infants were classified as large-for-gestational age (LGA) if their sex-specific birth weight for gestational age was greater than the 90th percentile of the US population fetal growth curves, while infants were classified as small-for-gestational age (SGA) if their birth weight was less than the 10th percentile [8].

Results

Participants and prevalence of gestational diabetes

Five pregnant women were excluded from the 176 consented participants due to vomiting following the glucose load. Table 1 shows that of the remaining 171 patients who completed the OGTT, 131 (76.6%) were Caucasians and 40 (23.4%) were Asian Americans. 49 (29%) and 28 (16%) ladies were determined to have GDM and GIGT, separately. Of the excess 94 members, 72 were Cau (55%) and 22 were AA (56.4%). Age, the number of weeks of gestation that were tested for the condition, the prepregnancy BMI, or parity did not distinguish the glucose tolerance groups in any significant way. As can be

seen, AA women had a higher prenatal BMI (P 0.003) and higher parity (P 0.001) than Caucasian women [9].

Comparison of measures of insulin sensitivity and insulin secretion in pregnant subjects

The overall level of agreement between the two measures of insulin sensitivity was low for all pregnant women ($r = 0.61$, $P = 0.001$). Commonness of insulin obstruction was higher utilizing evaluations of insulin awareness from the ISOGTT than involving fasting values to order ladies as insulin safe. 23% (11 Caucasian and 5 AA) of the women tested had no decreased insulin sensitivity when compared to the ISOGTT. 5 Caucasian women with GDM, 1AA, and 2 Caucasian women with GIGT were not found to have insulin resistance by the HOMA-IR. IGI/HOMA-IR and CIRgp, two measures of insulin secretion, were highly correlated ($r = 0.74$; $P < 0.0001$). Unfortunate insulin responsiveness to a glucose challenge was clear in both AA and Cau ladies that had diabetes.

Metabolic measures

In the NGT-abnGCT group, the evaluation of fasting insulin resistance revealed the greatest sensitivity, with GIGT having HOMA-IR values that were comparable to GDM (P 0.001). GDM and GIGT were significantly less sensitive than NGT-abnGCT in AA women, whereas Cau women's sensitivity decreased from NGT-abnGCT to GIGT to the GDM group (P 0.02) over time. Glucose-stimulated measures revealed a distinct overall pattern, with the NGT-abnGCT group having the highest SIOGTT index, followed by the GIGT and GDM groups (P 0.01), respectively. Steady with fasting measures, in AA ladies, both GDM and GIGT SIOGTT values contrast from NGT-abnGCT however not one another, though in Cau ladies, both NGT-abnGCT and GIGT subjects were altogether more touchy than the GDM subjects (P < 0.003). As shown in Figure, pregnant AA women were generally less sensitive than Caucasian counterparts [10]. The three study groups' observed glycemic trends were supported by an examination of the overall insulin secretion. CIRgp was highest for all pregnant women in NGT-abnGCT, followed by GIGT and GDM (P 0.002). NGT-abnGCT had the highest CIRgp in Caucasian pregnant women compared to GIGT and GDM, which were the same. In pregnant AA ladies, CIRgp was most noteworthy in GIGT and NGT-abnGCT gatherings while in CIRgp was fundamentally lower in GDM (P < 0.007). Compared to Caucasian women, non-diabetic AA women have a significantly higher CIRgp, whereas diabetics do not differ by race, as shown. In comparison to the GDM and GIGT groups, insulin secretion was highest in the NGT-abnGCT group (P 0.006). The IGI/HOMA-IR was significantly higher (P 0.03) in AA pregnant women than in Cau subjects [11].

Maternal and perinatal outcomes

165 women who gave birth at Woman's Hospital, of which 127 (or 77 percent) were Caucasians and 38 (or 23 percent) were African-American. Six patients (4 GDM, 2 NGT-abnGCT) conveyed somewhere else. Infants born to NGT-abnGCT mothers had significantly higher birth weights than those born to GDM mothers (P 0.014; Table 2). Eight (17%) newborn children from GDM moms, seven (23%) babies from GIGT mother and 27 (30%) infants of mother with NGT-abnGCT were LGA (Table 1). There were no consistent differences between the glucose tolerance groups in terms of gestational age, gender, or the number of Apgar scores below 7 at 1 and 5 minutes. Gender, gestational age-specific weight, or gestational length were not found to be influenced by race or race by diagnosis [12].

Discussion

In current clinical practice, ladies with GDM are recognized based on hyperglycemia on routine glucose resilience testing in pregnancy. We report our institutional involvement in the 100-g OGTT in which glucose and insulin levels were assessed in the fasting state and after an oral glucose load in a companion of pregnant ladies across the glycemic range. Adding insulin levels to the OGTT gave a more clear image of the unobtrusive metabolic irregularities in both insulin responsiveness and β -cell capability in this in danger pregnant populace [13]. Different agents recommended the utilization of fasting measure, for example, HOMA-IR as an option yet touchy evaluating test for GDM, which stays away from oral organization of glucose-containing arrangements. While the OGTT-derived insulin sensitivity assessment was correlated with the HOMA-IR, we discovered that the HOMA-IR provided a weaker predictive index than the glucose-stimulated ISOGTT measure. Moreover, in light of OGTT-

determined files of insulin discharge, it was very evident that β -cell capability continuously disintegrates with deteriorating of glucose resistance, reliable with results acquired in different examinations. Like the ISSI record previously revealed by Retnakaran et al. as a novel integrated measure of insulin sensitivity in relation to insulin secretion, we calculated an IS-SI for each pregnant patient [14]. We found that women with GDM and GIGT had greater glycemia, insulin sensitivity, and insulin secretion when compared to NGT-abnGCT. All pregnant women with GDM had poor-cell insulin resistance compensation. A restriction of this study is that main ladies who bombed the GCT went through OGTT evaluation and thusly every one of the pregnant ladies examined had some unpretentious weakness in insulin activity. A further restriction is that the evaluations of insulin activity have been made on estimations in light of the OGTT, and not by a "highest quality level" test, euglycemic brace review. Because clamp studies can't be done with a lot of people, population studies are using the indices [15].

Conclusions

In outline, antepartum OGTT screening distinguishes carb prejudice that happens when insulin discharge is lacking to make up for the insulin opposition of pregnancy. The work introduced here contends that insulin measures alongside glucose conclusions during oral glucose resistance testing give significant screening test data which is racially different and future work ought to look at the prescient worth of determined insulin activity files for the determination of GDM risk in an enormous planned ethnically-different partner. Although less severe than overt diabetes mellitus, hyperglycemia during pregnancy is associated with an increased risk of adverse maternal and fetal outcomes that is independent of the degree of metabolic disturbance. Pregnancy glycemia, insulin responsiveness, and insulin emission all add to posterity adiposity and macrosomia, and might be discrete focuses for intercession to streamline birth results and later posterity wellbeing.

Acknowledgement

None

Conflict of Interest

None

References

- Barnard K, Thomas S, Royle P (2010) Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. *BMC Pediatr* 10: 50.
- Mattila TK, de Boer A (2010) Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. *Drugs* 70: 2229-2245.
- Ly TT, Gallego PH, Davis EA (2009) Impaired awareness of hypoglycemia in a population-based sample of children and adolescents with type 1 diabetes. *Diabetes Care* 32: 1802-1806.
- American Diabetes Association (2013) Standards of medical care in diabetes-2013. *Diabetes Care* 36: 6-11.
- Benhamou PY, Catargi B, Delenne B (2012) Real-time continuous glucose monitoring (CGM) integrated into the treatment of type 1 diabetes: consensus of experts from SFD, EVADIAC and SFE. *Diabetes Metab* 38: 67-83.
- Ly TT, Hewitt J, Davey RJ (2011) Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucose monitoring in adolescents with type 1 diabetes. *Diabetes Care* 34: 50-52.
- Craig M, Hattersley A, Donaghue K (2009) Definition, epidemiology and classification of diabetes in children and adolescents. *Pediatr Diabetes* 10: 3-12.
- Kantarova D, Buc M (2007) Genetic susceptibility to type 1 diabetes mellitus in humans. *Physiol Res* 56: 255-266.
- Ehehalt S, Dietz K, Willasch AM, Neu A (2012) Prediction model for the incidence and prevalence of type 1 diabetes in childhood and adolescence: evidence for a cohort-dependent increase within the next two decades in Germany. *Pediatr Diabet* 13: 15-20.
- Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet* 358: 221-229.
- Rabinovitch A (2000) Autoimmune diabetes. *Sci Med* 7(3): 18-27.
- Pociot F, McDermott MF (2002) Genetics of type 1 diabetes mellitus. *Genes Immun* 3(5): 235-249.
- Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, et al. (2010) Genetics of type 1 diabetes: what's next? *Diabetes* 59(7): 1561-1571.
- Swift PG (2009) Diabetes education in children and adolescents. *Pediatr Diabetes* 10: 51-57.
- Brink S, Laffel L, Likitmaskul S (2009) Sick day management in children and adolescents with diabetes. *Pediatr Diabetes* 12: 146-153.